Verisante Technology continues funding for Aura device
Staff reports · Dermatology Times · 2012
Verisante Technology has renewed its Collaborative Research Agreement with the BC Cancer Agency, which will include Verisante’s contribution of approximately $250,000 to fund continued development of its Aura device for skin cancer detection.